| Erin Burkhart |
Erin Burkhart is currently the Chief Accounting Officer & Group Vice President at BioMarin Pharmaceutical, Inc. Prior to this, she worked at Eli Lilly & Co. as the Associate VP-US Gross-to-Net Business Analysis from 2014 to 2022. Ms. Burkhart received her undergraduate degree from Butler University. |
| Jeffrey Robert Ajer |
Jeffrey Robert Ajer is an Independent Director at Nektar Therapeutics since 2017. He is also the Chief Commercial Officer & Executive VP at BioMarin Pharmaceutical, Inc. since 2005. Previously, he worked as the Director-Purchasing Worldwide at Bausch Health Americas, Inc. from 1986 to 1999. He also held positions at SangStat Medical Corp., True North Therapeutics, Inc., and Genzyme Corp. In terms of education, Mr. Ajer completed his undergraduate degree and MBA at the University of California, Irvine. |
| Eduardo E. von Pervieux |
Eduardo E. von Pervieux is currently the Chief Information Officer at BioMarin Pharmaceutical, Inc. He previously worked as an Executive Director at Amgen, Inc. and as a Director of Business Process & Technology at Pfizer Inc. Mr. von Pervieux received his undergraduate degree from Florida International University and his graduate and MBA degrees from the University of Miami. |
| Philip Lo Scalzo |
Philip Lo Scalzo is currently the Chief Compliance Officer & Senior Vice President at BioMarin Pharmaceutical, Inc. He previously worked as an Associate Attorney at Sedgwick LLP and as an Assistant General Counsel at Sanofi-Aventis U.S. LLC. He completed his undergraduate degree at Boston College and his graduate degree at Brooklyn Law School. |
| Kevin Eggan |
Kevin Eggan is the founder of Enclear Therapies, Inc., Q-State Biosciences, Inc., QurAlis Corp. He is currently the Group VP, Head-Research & Early Development at BioMarin Pharmaceutical, Inc. His former positions include Director-Stem Cell Biology at The Broad Institute, Inc. and Professor at Harvard University. Eggan holds a doctorate from the Massachusetts Institute of Technology and an undergraduate degree from the University of Illinois. |
| Humaira Serajuddin |
Humaira Serajuddin is currently the Chief Marketing Officer & Senior Vice President at BioMarin Pharmaceutical, Inc. She holds an MBA from New York University and an undergraduate degree from Barnard College. |
| Brinda Balakrishnan |
Brinda Balakrishnan had a career history that included founding Vision Medicines, Inc. in 2013, where she held the title of VP-Corporate Strategy & Product Development from 2013 to 2016. Currently, she is an Independent Director at Aurinia Pharmaceuticals, Inc. since 2021 and the Chief Business Development Officer & SVP at BioMarin Pharmaceutical, Inc. since 2016. Dr. Balakrishnan has an educational background that includes undergraduate and doctorate degrees from the Massachusetts Institute of Technology and a doctorate degree from Harvard Medical School. |
| Amy Wireman |
Amy Wireman is currently working as the Chief People Officer at BioMarin Pharmaceutical, Inc. She started this job in 2013 and is still currently employed there. Ms. Wireman completed her undergraduate degree at New York University. |
| C. Greg Guyer |
C. Greg Guyer is currently the Director at The University of Georgia Research Foundation, Inc. He is also the Chief Technical Officer & Executive Vice President at BioMarin Pharmaceutical, Inc. Dr. Guyer previously worked as the Senior Vice President-Operations at Bristol-Myers Squibb World Wide Medicines Group. He holds a doctorate degree from American University, an MBA degree from Lehigh University, and an undergraduate degree from the University of Georgia. |
| Stuart Bunting |
Stuart Bunting has worked as the Vice President & Head-Research at BioMarin Pharmaceutical, Inc. since 2008. |
| Richard A. Meier |
Richard A. Meier is currently the Chairman at BioMarin Pharmaceutical, Inc. He is also the Co-Managing Director at Intersect ENT International GmbH, Intersect ENT GmbH, and a Member-Supervisory Board at Syntellix AG. Additionally, he is a Partner at Atlas Rock Co. In his former positions, Mr. Meier served as the President, Chief Executive Officer & Director at Rockley Photonics Holdings Ltd. from 2022 to 2023. He was an Independent Director at STAAR Surgical Co. from 2009 to 2016. He also held the role of Principal at Greyhound Lines, Inc. Furthermore, he was the Chief Financial Officer & Executive Vice President at Bausch Health Americas, Inc. in 1999. From 2013 to 2018, he served as the CFO, Executive VP & President-International at Owens & Minor, Inc. Mr. Meier was the Chief Financial Officer & Executive Vice President at Teleflex, Inc. from 2010 to 2011. He held the position of Senior Vice President at Schroder & Co., Inc. from 1996 to 1998. Moreover, he was the President & Chief Operating Officer at Advanced Medical Optics, Inc. from 2007 to 2009. He also served as the Chief Financial Officer & Executive Vice President at Intersect ENT, Inc. from 2019 to 2022. Additionally, he held the role of Principal at Australian Capital Equity Pty Ltd., Manufacturers Hanover Corp., and Salomon Smith Barney, Inc.Mr. Meier completed his undergraduate degree at Princeton University. |
| Jean-Jacques Bienaimé |
Jean-Jacques Bienaimé is currently serving as an Independent Director at Incyte Corp., BioMarin Pharmaceutical, Inc., Biotechnology Innovation Organization, Immunome, Inc., Pharmaceutical Research & Manufacturers of America, and Longwood Fund Management LLC. He previously held positions as Chairman, President & Chief Executive Officer at SangStat Medical Corp. and Genencor International, Inc. He also served as a Director at Genentech, Inc., InterMune, Inc., Aerogen, Inc., Genzyme Corp., Ensemble Therapeutics Corp., Portola Pharmaceuticals LLC, Vital Therapies, Inc., Saegis Pharmaceuticals, Inc., NeurogesX, Inc., and The Fox Chase Cancer Center. Additionally, he worked as the General Manager-Advanced Therapeutic & Oncology at Rhone-Poulenc Rorer Pharmaceuticals, Inc. Mr. Bienaimé received his undergraduate degree from ESCP Europe Campus Paris and ESCP Business School. He also holds an MBA from The Wharton School of the University of Pennsylvania. |
| Brian R. Mueller |
Brian R. Mueller is currently the Chief Financial Officer & Executive VP-Finance at BioMarin Pharmaceutical, Inc. He is also a Member at The American Institute of Certified Public Accountants and a Vice President at Professional Control Corp. Previously, he served as an Independent Director at Anthera Pharmaceuticals, Inc. from 2014 to 2020. He also worked as a Senior Manager at KPMG LLP and as a Principal at Arthur Andersen LLP. Mr. Mueller completed his undergraduate degree at Northern Illinois University. |
| Henry J. Fuchs |
Henry J. Fuchs is currently the President-Worldwide Research & Development at BioMarin Pharmaceutical, Inc. He previously held positions as Director at IntraBiotics Pharmaceuticals, Inc., Independent Director at Genomic Health, Inc., Independent Director at Mirati Therapeutics, Inc., Independent Director at Ardea Biosciences, Inc., Principal at Genentech, Inc., and Chief Medical Officer & Executive Vice President at Onyx Pharmaceuticals, Inc. He obtained his undergraduate degree from Harvard University and his doctorate degree from George Washington University. |
| Alexander Hardy |
Alexander Hardy is currently the President, Chief Executive Officer & Director at BioMarin Pharmaceutical, Inc. He is also a Director at Pharmaceutical Research & Manufacturers of America and a Member of The Wall Street Journal CEO Council. Previously, he was the Chief Executive Officer & Director at Genentech, Inc. Hardy received his undergraduate degree from the University of Cambridge and his MBA from the Stephen M. Ross School of Business. |
| Mark J. Alles |
Mark J. Alles currently works at TORL Biotherapeutics LLC, as Chairman & Chief Executive Officer from 2024, Wugen, Inc., as Chairman from 2023, AI Proteins, Inc., as Chairman from 2023, BioMarin Pharmaceutical, Inc., as Independent Director from 2022, Juno Therapeutics, Inc., as Director, Misericordia University, as Trustee, and Acetylon Pharmaceuticals, Inc., as President. Mr. Alles also formerly worked at Celgene Corp., as Chairman & Chief Executive Officer from 2018 to 2019, Turning Point Therapeutics, Inc., as Chairman from 2021 to 2022, Biotechnology Innovation Organization, as Director, Pharmaceutical Research & Manufacturers of America, as Director, European Federation of Pharmaceutical Industries & Assns, as Director, Gilda's Club New York City, Inc., as Director, Syros Pharmaceuticals, Inc., as Independent Director from 2019 to 2023, Antengene Corp. Ltd., as Independent Non-Executive Director from 2020 to 2023, Centocor, Inc., as Principal, Bayer Corp., as Principal, Aventis Pharmaceuticals, Inc., as Vice President-Oncology Business Unit from 1993 to 2004, and HealthCare Institute of New Jersey, as Trustee. Mr. Alles received his undergraduate degree in 1981 from Lock Haven University of Pennsylvania. |
| Robert J. Hombach |
Robert J. Hombach is an Independent Director at BioMarin Pharmaceutical, Inc., a Director at EDGe Surgical, Inc., an Independent Director at Embecta Corp., and an Industry Advisor at Agent Capital LLC. He was previously an Independent Director at CarMax, Inc. from 2018 to 2022, a Director at Naurex, Inc., a Director at Loyola University Health System, the President & Director at Baxter International Foundation, and an Independent Director at Aptinyx, Inc. from 2018 to 2023. He also served as the Chief Financial Officer & Vice President at Baxter International, Inc. from 2011 to 2015 and as the Executive VP, Chief Operations & Financial Officer at Baxalta, Inc. from 2015 to 2016. Hombach received his undergraduate degree from The University of Colorado in 1988 and his MBA degree from Kellogg School of Management in 1997. |
| David E. I. Pyott |
David E. I. Pyott is currently the Chief Executive Officer & Director at Serica Technologies, Inc. He is also the Chairman at Bioniz Therapeutics, Inc., Vice Chairman at Chapman University, Chairman-Governing Board at London Business School, Independent Director at BioMarin Pharmaceutical, Inc., Director at MAP Pharmaceuticals LLC, Director at Biotechnology Innovation Organization, Independent Director at Alnylam Pharmaceuticals, Inc., Director at Pan-American Ophthalmological Foundation, Director at Cosmetic Surgery Foundation, Inc., Director at Paul Merage School of Business, Independent Director at Pliant Therapeutics, Inc., Independent Member-Supervisory Board at Koninklijke Philips NV, President at Vicept Therapeutics, Inc., President at International Council of Ophthalmology Foundation, Vice President and President at Ophthalmology Foundation, and Trustee at California Institute of Technology. Formerly, Mr. Pyott served as the Chairman & Chief Executive Officer at Allergan, Inc., President & Chief Executive Officer at Sandoz Nutrition Corp., Lead Independent Director at Avery Dennison Corp., Independent Director at Edwards Lifesciences Corp., Director at Pacific Mutual Holding Co., Director at Pacific LifeCorp, Director at California Healthcare Institute, Director at Rani Therapeutics LLC, and Head-Nutrition Division at Novartis AG. Mr. Pyott holds a graduate degree from The University of Edinburgh and an MBA from London Business School (conferred in 1980). |
| May Kin Ho |
May Kin Ho is currently serving as a Director at PAREXEL International Corp., BioMarin Pharmaceutical, Inc., Agios Pharmaceuticals, Inc., FibroGen, Inc., The Aaron Diamond AIDS Research Center, Parexel International Corp. Ltd., Institute For Protein Innovation, Inc., Neumora Therapeutics, Inc., and as a Venture Partner at Qiming Venture Partners Ltd. Dr. Ho is also the Managing Partner at Viridian Global Logistics, Inc. In the past, Dr. Ho held positions as an Independent Director at PAREXEL International Corp., GRAIL LLC, and as a Director-Strategic Planning, Marketing & Research at DuPont Merck Pharmaceutical Co. and Dupont De Nemours & Co., Inc. Dr. Ho also worked at The Goldman Sachs Group, Inc. as a Partner & Co-Head-Healthcare and at Goldman Sachs & Co. LLC as a Research Analyst. Dr. Ho obtained a doctorate degree from the State University of New York at Downstate Medical Center in 1980 and an undergraduate degree from the same institution in 1975. |
| Willard H. Dere |
Willard H. Dere is currently serving as an Independent Director at BioMarin Pharmaceutical, Inc., Mersana Therapeutics, Inc., and Seres Therapeutics, Inc. He is also a Professor and Executive Director of Personalized Health at The University of Utah Health Sciences Center. Additionally, he holds positions as a Director at Peel Therapeutics, Inc., Metagenomi, Inc., and Angitia Biopharmaceuticals Guangzhou Ltd. Dr. Dere previously served as an Independent Director at Radius Health, Inc. and OCERA Therapeutics LLC. He also held positions at Clinical & Translational Science Institute, Metagenomi Technologies LLC, Amgen, Inc., Eli Lilly & Co., and The Indiana University School of Medicine. Dr. Dere's educational background includes an undergraduate degree and a doctorate from the University of California, Davis. |
| Dennis Joseph Slamon |
Dennis Joseph Slamon is currently the Executive Vice Chairman-Research at the University of California, Los Angeles. He is also an Independent Director at BioMarin Pharmaceutical, Inc. and the Director-Revlon & UCLA Women Cancer Research at the David Geffen School of Medicine. Additionally, he holds the positions of Executive Director at Translational Research In Oncology and President & Director at Translational Research In Oncology - Us, Inc. Since 1995, he has been the Director-Clinical & Translational Research at the Jonsson Comprehensive Cancer Center. Dr. Slamon completed his undergraduate degree at Washington & Jefferson College in 1970 and received his doctorate from the Pritzker School of Medicine in 1975. |
| Athena M. Countouriotis |
Athena M. Countouriotis is currently the Chief Executive Officer & Chief Financial Officer at Avenzo Therapeutics, Inc. She is also the Chairman at Recludix Pharma, Inc., Capstan Therapeutics, Inc., and BioMarin Pharmaceutical, Inc. Additionally, she serves as an Independent Director at Iovance Biotherapeutics, Inc., Director at NuMedii, Inc., Independent Director at Passage Bio, Inc., and Director at Leal Therapeutics, Inc. Previously, Athena held the positions of President, Chief Executive Officer & Director at Turning Point Therapeutics, Inc., Director-Oncology Global Clinical Research at Bristol Myers Squibb Co., and Associate Medical Director at CTI BioPharma Corp. She was also an Independent Director at Cardiff Oncology, Inc., Chief Medical Officer & Senior Vice President at Halozyme Therapeutics, Inc., Chief Medical Officer at Ambit Biosciences Corp., and Chief Medical Officer & Senior Vice President at Adverum Biotechnologies, Inc.Athena completed her undergraduate studies at the University of California, Los Angeles and obtained her doctorate degree from Tufts University School of Medicine. |
| Mark Joseph Enyedy |
Mark Joseph Enyedy is currently an Independent Director at BioMarin Pharmaceutical, Inc., a Director at Biotechnology Innovation Organization, a Director at American Cancer Society, New England Division, Inc., and an Independent Non-Executive Director at Ergomed Plc. Previously, he served as the President, Chief Executive Officer & Director at ImmunoGen, Inc. from 2016 to 2024, the Chief Executive Officer & Director at Proteostasis Therapeutics, Inc. from 2011 to 2013, an Independent Director at Keryx Biopharmaceuticals, Inc. from 2017 to 2018, an Independent Director at Akebia Therapeutics, Inc. from 2018 to 2021, an Independent Director at Fate Therapeutics, Inc. from 2012 to 2018, and an Independent Director at LogicBio Therapeutics, Inc. from 2020 to 2022. He also held positions at Genzyme Corp. as SVP, President-Transplant & Multiple Sclerosis from 2011 to 2012, and at Shire Plc as Executive VP & Head-Corporate Development from 2014 to 2016. Additionally, he worked as an Associate at Palmer & Dodge LLP. Mr. Enyedy received his undergraduate degree from Northeastern University and his graduate degree from Harvard Law School. |
| Barbara W. Bodem |
Barbara W. Bodem is currently serving as a Director at DJO Global, Inc. She is also an Independent Director at Enovis Corp., BioMarin Pharmaceutical, Inc., Option Care Health, Inc., and BiomEdit LLC. Additionally, she holds the position of Co-President & Director at Hill ROM Co, Inc. In her former roles, Ms. Bodem has served as an Independent Director at Invacare Corp., Turning Point Therapeutics, Inc., and Syneos Health, Inc. She was also the Chief Financial Officer & Senior Vice President at Hill-Rom Holdings, Inc. Furthermore, she has worked as a Principal at Eli Lilly & Co., Vice President-Global Commercial Finance at Hospira, Inc., and Senior Vice President-Finance at Mallinckrodt Plc. She has also held the position of Chief Financial Officer at Lilly Oncology and Dentsply Sirona, Inc.Ms. Bodem completed her undergraduate studies and earned an MBA from Indiana University. |
